Enanta Pharmaceuticals Inc. reported its financial results for the first quarter ended December 31, 2025. Revenue for the period was USD 18.62 million. Research and development expenses totaled USD 20.86 million, while general and administrative expenses were USD 9.01 million. Net loss for the quarter was USD 11.90 million, or a loss of USD 0.42 per diluted common share. As of December 31, 2025, Enanta Pharmaceuticals Inc. held cash, cash equivalents, and short-term and long-term marketable securities totaling USD 241.90 million. The company expects this liquidity, together with retained royalty revenue, to be sufficient to fund its existing business and development programs into fiscal 2029. During the quarter, Enanta Pharmaceuticals Inc. advanced its virology pipeline, including preparations for a Phase 3 study of its leading oral RSV treatment candidates, zelicapavir and EDP-323, both of which have received Fast Track designation from the U.S. Food and Drug Administration. The company also expanded its immunology pipeline with a third program targeting oral MRGPRX2 inhibitors for type 2 immune-driven diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enanta Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260209293558) on February 09, 2026, and is solely responsible for the information contained therein.